Research using a preclinical estrogen receptor-positive (ER+) breast cancer model revealed that lifetime genistein consumption decreases the likelihood of de novo, acquired tamoxifen resistance, and tumor relapse. This evidence concerns the gene ESR1 and breast carcinoma.